ICIs in Melanoma: Predicting Immune-related Adverse Events

 Melanoma histopathology predicted which patients were most likely to develop immune-related adverse events while taking checkpoint inhibitors.
Medscape Medical News

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart